Current Edition

Gene Therapy Products for Life-Threatening Diseases are getting the Green Light

Through this article, Jaime Polychrones at Clarivate Analytics
draws attention to the memorable 2017, when the US Food and
Drug Administration (FDA), for the first time in its history, approved
a biologics licence application (BLA) for a gene therapy product.
Kymriah (tisagenlecleucel), a first-in-class CD19-directed genetically
modified autologous T-cell immunotherapy developed by Novartis
Pharmaceuticals Corporation, is indicated for the treatment of patients
up to age 25 years with B-cell precursor acute lymphoblastic leukaemia
that is refractory or in second or later relapse. This approval came on
the heels of a unanimous vote to support licensure of the product
during an FDA Oncologic Drugs Advisory Committee meeting.